EUVIMEDEUVIMED entdecken
Crossref

Impact of Cell‐Free and Concentrated Ascites Reinfusion Therapy on eGFR

Ryo Takaki iD, Kaori Kohatsu, Shigeki Kojima iD, Yugo Shibagaki, Tomoya Nishino iD, Tsutomu Sakurada

Therapeutic Apheresis and Dialysis · 14.07.2026

DOI: 10.1002/1744-9987.70188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 14.07.2026. Verfasst von Ryo Takaki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whether cell‐free and concentrated ascites reinfusion therapy (CART) improves renal function remains unclear. We investigated the effects of CART on renal function.

Methods

We retrospectively analyzed changes in renal function after CART in 157 patients (264 sessions) with or without chronic kidney disease (CKD) who underwent the treatment between June 1, 2010, and March 31, 2022.

Results

The most common underlying disease was malignant ascites (93.6%), most frequently caused by breast ( n = 49, 31.2%) and ovarian ( n = 31, 19.7%) cancers. The mean patient age was 61.6 ± 12.2 years (women, 82.1%). The median processed ascites volume was 4.26 [3.40–6.43] L, and the mean number of CART sessions per patient was 1.66 ± 1.38. No severe adverse events were observed. The estimated glomerular filtration rate (eGFR) significantly increased after CART (from 64.5 [47.5–82.9] to 65.1 [50.5–85.6] mL/min/1.73 m 2 ; p = 0.004), particularly in patients with CKD stage G3b and G4 (G3b: from 35.4 [33.0–38.6] to 45.9 [36.1–52.5] mL/min/1.73 m 2 ; p = 0.005, G4: from 25.1 [21.0–26.8] to 27.3 [21.1–35.3] mL/min/1.73 m 2 ; p = 0.045).

Conclusion

CART may be associated with an increase in eGFR, particularly in patients with CKD.

Schlagwörter

Stichwörter der Autor:innen

ascitescell‐free and concentrated ascites reinfusion therapyeGFRrenal function

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Nephrology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
  • Department of Internal Medicine, Division of Nephrology and Hypertension, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
  • Kojima Kidney and Dialysis Clinic, Yokohama, Kanagawa, Japan.
  • Department of Internal Medicine, Division of Nephrology, Nagasaki University Hospital, Nagasaki, Japan.

ORCID-Profile: Ryo Takaki, Shigeki Kojima, Tomoya Nishino

Zitieren

APA

Takaki, R., Kohatsu, K., Kojima, S., Shibagaki, Y., Nishino, T., & Sakurada, T. (2026). Impact of Cell‐Free and Concentrated Ascites Reinfusion Therapy on eGFR. Therapeutic Apheresis and Dialysis. https://doi.org/10.1002/1744-9987.70188

Vancouver

Takaki R, Kohatsu K, Kojima S, Shibagaki Y, Nishino T, Sakurada T. Impact of Cell‐Free and Concentrated Ascites Reinfusion Therapy on eGFR. Therapeutic Apheresis and Dialysis. 2026. doi:10.1002/1744-9987.70188

BibTeX
@article{Takaki2026,
  author = {Takaki, Ryo and Kohatsu, Kaori and Kojima, Shigeki and Shibagaki, Yugo and Nishino, Tomoya and Sakurada, Tsutomu},
  title = {Impact of Cell‐Free and Concentrated Ascites Reinfusion Therapy on eGFR},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2026},
  doi = {10.1002/1744-9987.70188}
}
Kostenlos starten →